Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology

Long-Term Tracking: MRI and Clinical Monitoring

At a Glance

SPMS monitoring combines regular neurologic exams, walking and hand-function tests, and individualized brain MRI rather than relying on scans alone. Ongoing care also includes bone, cardiovascular, and skin checks, vaccination planning, and prompt review of sudden or persistent new symptoms.

Monitoring Secondary Progressive Multiple Sclerosis (SPMS) is a marathon, not a sprint. Because the disease moves slowly, “surveillance” isn’t just about looking for new spots on an MRI; it’s about carefully tracking small changes in how your body functions over years [1]. This requires a consistent, individualized schedule of both clinical exams and imaging to distinguish true disease progression from normal daily fluctuations [2][3].

Clinical Surveillance Schedule

Your neurologist will typically recommend a formal assessment every 6 to 12 months, tailored to your specific needs, age, and treatments [4][3]. During these visits, the focus is on three key “performance” measures. To get the most accurate data, these tests should be performed the same way every time to account for “practice effects”.

  • EDSS (Expanded Disability Status Scale): This is the standard “ruler” for MS disability. In SPMS, a change is usually only considered “confirmed” if it is still present on a repeat test 6 months later [2][5].
  • T25FW (Timed 25-Foot Walk): This tracks your walking speed. A 20% increase in the time it takes you to walk 25 feet is a hallmark of meaningful progression in research [2][6].
  • 9HPT (9-Hole Peg Test): This measures your hand and arm coordination. Like the walking test, a 20% change in your time suggests that the disease is affecting your upper-body function [2][6].

Modern MRI Protocols for SPMS

Imaging in SPMS has changed. While MRI was used in earlier stages to find “active” inflammation, it is now used to monitor the slow loss of brain tissue (atrophy) and the development of “slowly expanding lesions” [7][8].

  • 3D FLAIR: This is a highly useful sequence for MS brain MRIs when available [7][9]. It provides a high-resolution view that makes it easier for radiologists to compare this year’s scan to last year’s. (Slowly expanding lesions, or SELs, are primarily an emerging research concept and may not be routinely measured on standard clinical reports).
  • Judicious Gadolinium Use: In the RRMS phase, gadolinium (contrast dye) was used to find “enhancing” lesions. In SPMS, however, progression often happens without these active, enhancing spots [10]. Current guidelines suggest using gadolinium “judiciously”—only when it is needed to make a specific treatment decision or if there is a sudden, unexplained change in your symptoms [10].
  • Spinal Cord MRI: Unlike brain MRIs, spinal cord scans are not usually required every year [11]. They are typically reserved for when you have new “spinal” symptoms (like new bladder changes or leg numbness) or if your brain MRI looks stable but your physical walking ability is clearly worsening [12][13].

Looking Beyond the MS Diagnosis

As SPMS progresses, it can impact other parts of your health that aren’t strictly “neurological.” Long-term surveillance must include a focus on your overall well-being [14].

  • Bone Health: Reduced mobility and prior steroid use can lead to thinning bones (osteoporosis). Discuss with your doctor if a DEXA scan is appropriate to monitor your bone density and ensure you aren’t at high risk for fractures [15].
  • Cardiovascular Health: People with SPMS often have a higher risk of vascular issues like high blood pressure or high cholesterol [14]. Managing these is critical because “vascular comorbidities” (other health problems) are associated with worse MS outcomes [14].
  • Skin and Pressure Integrity: If your mobility is limited, your care team should help you monitor for pressure injuries (sores). Early detection of skin redness in areas where you sit or lie down can prevent serious infections [16].
  • Vaccination Status: Because some SPMS treatments can affect your immune system, staying up-to-date on vaccinations (like the flu, pneumonia, and shingles vaccines) is a vital part of your long-term safety plan [17]. Live vaccines may be unsafe during certain immune therapies and may need to be administered before you start a new DMT.

When to Seek Urgent Care

While SPMS changes are usually slow, you should contact your care team urgently if you experience:

  • An inability to pass urine, severe flank pain, or a high fever (signs of a potentially severe infection).
  • Sudden, severe weakness, vision loss, or trouble speaking.
  • Repeated, unexplained falls.
  • A new or clearly worsening neurologic symptom lasting more than 24 hours that is not explained by heat, fever, or an obvious infection.

Common questions in this guide

How often are clinical assessments usually done for SPMS?
A neurologist may recommend a formal assessment every 6 to 12 months, depending on your symptoms, age, treatments, and individual needs. Using the same testing methods each time makes it easier to distinguish true change from daily variation or familiarity with the tests.
Which tests can show whether SPMS disability is changing?
Common measures include the Expanded Disability Status Scale, a timed 25-foot walk, and the 9-hole peg test for hand coordination. A change that remains present on repeat testing may be more meaningful than a single result, and the commonly used 20% changes for walking or hand tests come mainly from research settings.
Does every SPMS brain MRI require gadolinium contrast?
No. Because SPMS progression can occur without active, contrast-enhancing lesions, gadolinium is often used selectively when it could affect a treatment decision or when symptoms change suddenly without an obvious explanation.
When might I need a spinal cord MRI for SPMS?
Spinal cord MRI is not usually needed every year. It may be considered if you develop new symptoms such as bladder changes or leg numbness, or if your brain MRI appears stable while your walking ability is clearly worsening.
What health checks should be part of long-term SPMS monitoring?
Monitoring may include bone-density evaluation when reduced mobility or past steroid use raises concern for osteoporosis, along with blood pressure and cholesterol checks. Your care team may also assess skin for pressure injuries and review vaccinations, especially before or during immune-affecting treatments.
Which new SPMS symptoms need urgent medical attention?
Seek urgent medical advice for inability to pass urine, severe flank pain with fever, sudden severe weakness, vision loss, trouble speaking, or repeated unexplained falls. A new or clearly worsening neurologic symptom lasting more than 24 hours also needs prompt review when it is not explained by heat, fever, or an infection.

Get notified when new evidence is published on secondary progressive multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.

    Adamczyk-Sowa M, Adamczyk B, Kułakowska A, et al.

    Neurologia i neurochirurgia polska 2020; (54(5)):384-398 doi:10.5603/PJNNS.a2020.0082.

    PMID: 33058113
  2. 2

    The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

    Cadavid D, Cohen JA, Freedman MS, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(1)):94-105 doi:10.1177/1352458516638941.

    PMID: 27003945
  3. 3

    Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.

    Tsagkas C, Naegelin Y, Amann M, et al.

    European journal of neurology 2021; (28(12)):4153-4166 doi:10.1111/ene.15098.

    PMID: 34487400
  4. 4

    Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.

    Blackstone J, Williams T, Nicholas JM, et al.

    BMJ open 2024; (14(9)):e086414 doi:10.1136/bmjopen-2024-086414.

    PMID: 39284697
  5. 5

    Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria.

    Ciron J, Gueguen A, Al Khedr A, et al.

    Revue neurologique 2022; (178(10)):1098-1104 doi:10.1016/j.neurol.2022.07.004.

    PMID: 36180289
  6. 6

    Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.

    Koch MW, Mostert J, Repovic P, et al.

    Neurology 2021; (96(1)):e111-e120 doi:10.1212/WNL.0000000000011123.

    PMID: 33106389
  7. 7

    2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.

    Wattjes MP, Ciccarelli O, Reich DS, et al.

    The Lancet. Neurology 2021; (20(8)):653-670 doi:10.1016/S1474-4422(21)00095-8.

    PMID: 34139157
  8. 8

    MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.

    Koch MW, Mostert J, Repovic P, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2022; (28(4)):561-572 doi:10.1177/13524585211031801.

    PMID: 34304609
  9. 9

    [New MRI guidelines for multiple sclerosis].

    Reith W, Hausmann A, Kettner M

    Der Radiologe 2022; (62(4)):322-326 doi:10.1007/s00117-022-00991-y.

    PMID: 35316355
  10. 10

    Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group.

    Rovira À, Doniselli FM, Auger C, et al.

    European radiology 2024; (34(3)):1726-1735 doi:10.1007/s00330-023-10151-y.

    PMID: 37658891
  11. 11

    Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.

    Hong J, Gaubert M, Lefort M, et al.

    Journal of neurology 2025; (272(4)):316 doi:10.1007/s00415-025-13068-2.

    PMID: 40186635
  12. 12

    Radiological Disease Activity in Secondary Progressive Multiple Sclerosis.

    Zohar DN, Magalashvili D, Dreyer-Alster S, et al.

    European neurology 2023; (86(2)):116-120 doi:10.1159/000527720.

    PMID: 36596291
  13. 13

    Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients.

    Vercellino M, Marasciulo S, Bosa C, et al.

    Journal of neurology 2025; (272(7)):482 doi:10.1007/s00415-025-13217-7.

    PMID: 40581711
  14. 14

    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.

    Salter A, Thomas NP, Tyry T, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2018; (24(7)):951-962 doi:10.1177/1352458517711274.

    PMID: 28524746
  15. 15

    Effects of Progressive Resistance Training on Cardiovascular Risk Factors in People With Progressive Multiple Sclerosis.

    Gravesteijn AS, Beckerman H, Willig M, et al.

    Archives of physical medicine and rehabilitation 2025; (106(11)):1694-1702 doi:10.1016/j.apmr.2025.04.004.

    PMID: 40268183
  16. 16

    Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study.

    Schreiber H, Penner IK, Maier T, et al.

    Journal of central nervous system disease 2024; (16()):11795735241296001 doi:10.1177/11795735241296001.

    PMID: 39449826
  17. 17

    The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.

    Moiola L, Barcella V, Benatti S, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2021; (27(3)):331-346 doi:10.1177/1352458520952311.

    PMID: 32940121

This page explains SPMS monitoring for informational purposes only and does not constitute medical advice. Your neurologist should determine your MRI and testing schedule and interpret changes in light of your symptoms and treatment.